The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack.
Seeger JM, Schmidt P, Brinkmann K, Hombach AA, Coutelle O, Zigrino P, Wagner-Stippich D, Mauch C, Abken H, Krönke M, Kashkar H.
Seeger JM, et al. Among authors: zigrino p.
Cancer Res. 2010 Mar 1;70(5):1825-34. doi: 10.1158/0008-5472.CAN-09-3175. Epub 2010 Feb 23.
Cancer Res. 2010.
PMID: 20179203